High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
about
The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor RASSF1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cellsMethylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.Characteristic promoter hypermethylation signatures in male germ cell tumorsAberrant CBFA2T3B gene promoter methylation in breast tumorsAnimal models to study the mutational landscape for oral cavity and oropharyngeal cancersCombination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expressionClinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastomaThe Ras-association domain family (RASSF) members and their role in human tumourigenesis.Hypermethylation of RASSF1A in human and rhesus placentas.Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China.OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.Epigenetic disruption of cell signaling in nasopharyngeal carcinoma.Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.Diagnostic Capacity of RASSF1A Promoter Methylation as a Biomarker in Tissue, Brushing, and Blood Samples of Nasopharyngeal Carcinoma.Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosisEpigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumorsFrequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemiaEpigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population.Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesisMethylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors.miR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesisEpigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinomaThe Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases.Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer.Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivoRASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.Epigenetic regulation of apoptosis and cell cycle in osteosarcomaExome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutationsInactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinomaGenetic and epigenetic analysis of erbB signaling pathway genes in lung cancerQuantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver.Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma.Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues.Oncogenic induction of cellular high CpG methylation by Epstein-Barr virus in malignant epithelial cellsTP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma.Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma.Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation.Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.
P2860
Q24297959-61A3C8AF-886C-46B1-A8AE-D55A1FB8C85FQ24302341-568B5E89-037F-4E6C-9F8C-B5475791BE84Q24794569-11D94B3B-08E6-4E92-8127-42886E1BB4C9Q24799928-5AD8DC8A-9251-4469-AB9A-4F813B0C5840Q24804804-11D11DBD-C7A9-4644-AEF0-DB8A07E9A495Q27026169-632AA6F7-A24B-4FF9-8370-096A7A0CA0CAQ28485457-5567DDCB-6C8E-4CE7-9246-924B32149102Q30781403-E387A888-54E0-459D-AC50-3ED95A13F8C7Q31121564-C61B4AB0-FD9D-4924-8F97-2EB8542F5D67Q33275493-D347938B-7ED8-4414-913E-31DBA7E4A9DEQ33289807-56C19E1F-884A-4106-97F6-9A0192B9E922Q33361612-13859243-1BA2-4029-8F69-9B3CCFD2441CQ33579472-A53864E9-A75D-4EED-8E69-05F9F645AF55Q33594982-68F3AD18-0F2D-4316-8E3E-BF9BD22EE04BQ33603685-F824479C-F222-49A7-B7A4-C01AA8FD430DQ33721470-DC795B2A-54C4-4F88-A823-C314992F3B4CQ33726187-CB405788-676E-43A4-BED0-D341BF833F21Q33840913-A978C190-D2CE-485C-961B-BBAA51FA9114Q33887581-12686E28-A4C0-42A0-8CB8-50574DFBBC7EQ33959044-35055D9B-8C10-4191-84CC-250BCF0BBB0FQ33991964-24E41C81-BE59-4120-BB80-3400913D24B2Q34023389-49642B2B-68A5-486E-833A-359091164AC0Q34050917-11243518-7C40-45B2-87FE-60EC7E7BEBFBQ34099074-B79FE56E-4425-4B43-B135-FFA6F359A76FQ34183409-130E1A2C-E1C2-45A8-8B86-D44563A1EE7BQ34247124-4D19A7CE-106F-428A-A87A-FC8578C8B719Q34268708-1F0350A6-391E-4BC3-A9B9-CC9FD1D73753Q34323619-CAD2A55E-78C2-46D8-B901-12FA0E317D32Q34495498-D4E3C49C-E680-4F1C-B6F7-D35E888C680EQ34549536-F5C46DC7-D1CF-41DF-93C3-7206A304D189Q34605107-47425D5E-010C-467A-9F6E-600573EEFFF2Q34674319-476448C1-ED1F-482B-BFBE-0780129E3AAEQ34681945-E04113A5-7223-4A7C-9562-5E51673AF428Q34725003-17727985-B16A-4387-B523-EC9C8EC59875Q34769720-EC7830EC-5446-43F8-8D5D-ED76212E5D55Q35020438-9179E6B6-6DA8-4F5A-BA12-EA37A8A84DE6Q35368917-26839A38-11E4-46B7-AD3B-516418D73CD3Q35788760-726AF370-F596-4601-BE17-0B8201A4C90AQ35792108-824F42E7-57A0-440B-9F6D-DCE8C8DDBB5DQ35792134-19C87680-D188-4137-9510-2ACEFEC0B989
P2860
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@ast
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@en
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@nl
type
label
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@ast
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@en
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@nl
prefLabel
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@ast
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@en
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@nl
P2093
P1433
P1476
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
@en
P2093
Johnson PJ
P304
P407
P577
2001-05-01T00:00:00Z